Georges JOURDI

Professor in Hematology (PU-PH) at Université Paris Cité & Assistance Publique des Hôpitaux de Paris

[NEJM @NEJM]

In the phase 3 OCEANIC-STROKE trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. Full trial results: https://t.co/UPJGedYXFe

Editorial: Asundexian for Noncardioembolic Ischemic Stroke https://t.co/V1dVNbx4T8

[Marc Carrier @MarcCarrier1]

Managing recurrent VTE despite anticoagulation in patients with cancer is tough ⚠️

This “How I Treat” review highlights practical strategies (confirm recurrence 🔍, assess adherence/interactions 💊, LMWH escalation or switch 📈) - More data needed! 📊
https://t.co/Asevq0atLk
@BloodPortfolio

[Georges JOURDI @GJERDI]

@2Scottish @AnuAggarwal86 Congrats! 🥳

[NEJM @NEJM]

In untreated chronic lymphocytic leukemia, fixed-duration venetoclax-based regimens were noninferior to continuous ibrutinib with regard to 3-year progression-free survival and were associated with higher MRD-negative rates. Full phase 3 CLL17 trial results and Research Summary: https://t.co/EQfrJ06UXj

[ISTH @isth]

If you attended #ISTH2025, you may have had the chance to hear about the COBRRA trial during our late-breaking research session! COBRRA is the FIRST head to head trial of apixaban vs rivaroxaban in the management of acute VTE.

Read the article here: https://t.co/9Kf4rApXLA

[NEJM @NEJM]

In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period.

Full COBRRA trial results: https://t.co/tvPYrBCWj8

[Thomas Reiser @TomReiser]

The @ISTH #SSC Subcom. on Platelets in Health & Disease is conducting a project to identify crit. patterns & mgmt strat. that may inform future care GLs for adult Glanzmann Thrombasthenia (GT) patients w/art. thromb. events.
Learn more & particiate at: https://t.co/K2PWoa8IBi

[Georges JOURDI @GJERDI]

@2Scottish @edelyn_park Congrats @2Scottish 🎉

[Yüksel Ürün @DrYukselUrun]

BREAKING from @NEJM
In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is :
🔘Noninferior to full-dose (5 mg BID) for VTE recurrence
🔘Lower bleeding risk (12.1% vs. 15.6%)
🔘Safer extended anticoagulation, same protection.
#Thrombosis #cancer @OncoAlert @Cihan_Ay_MD
DOI: 10.1056/NEJMoa2416112

[Georges JOURDI @GJERDI]

#ISTH2026

[caterina casari @caterinacasari]

Thanks @SFTHemostase!!

[SFTH @SFTHemostase]

Le prochain congrès @SFTHemostase sera a Lyon, organisé par les équipes de Lyon et de Genève, du 1er au 3 octobre 2025 !

[Congrès de la SFTH @SFTH_2025]

AntiXI dans le cancer, une présentation très claire par le Pr @LaurentBertole1 ! @SFTHemostase #hemostase #thrombose #CFH2024

[Congrès de la SFTH @SFTH_2025]

La masterclass Flux continue avec Benoit Ho-Tin-Noé sur la modélisation de la thromboinflammation veineuse. #thrombose #sfth #flux

[Congrès de la SFTH @SFTH_2025]

Mercredi 11 septembre au #CFH2024 c'est la Masterclass Thromboprophylaxie périopératoire avec Stéphanie Roullet et Thomas Quemeneur! @SFTHemostase #hemostase

[Congrès de la SFTH @SFTH_2025]

Mercredi 11 septembre au #CFH2024 c'est la masterclass Modèles d'étude de l'hémostase et de la thrombose en flux avec Benoit Ho-Tin-Noé et Pierre Mangin! @SFTHemostase #hemostase #thrombose

[sophie susen @sophie_susen]

Esteemed colleague and leader in the field of hemostasis, Pr Nigel Key will be our guest of honor for the 2024 congress of the French Society of Hemostasis and Thrombosis @SFTH #CFH2024 @cfh_2024
We are very much looking forward to his keynote lecture on tranexamic acid

[Congrès de la SFTH @SFTH_2025]

📣 Le #CFH2024 c'est dans 2 semaines!
On n'oublie pas de s'inscrire
👉https://t.co/2KJ24AV2Xi
Petits conseils pour la valise : on pense au ☂ et 👟 adaptées en prévision d'une éventuelle drache 🌧

[Congrès de la SFTH @SFTH_2025]

Le vendredi 13 septembre au #CFH2024 c’est l’occasion d’écouter Yacine Boulaftali expliquer le rôle des plaquettes dans l’hémorragie cérébrale et dans la formation et la rupture des anévrismes. On aurait tord de rater cette session ! @SFTHemostase @la_SFNV #hemostase #plaquettes

[Georges JOURDI @GJERDI]

Let the show begin!